Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown
Daily 1-pager M&A Snapshot for Deal Makers
Oct 3 (Reuters) – Shares of LogicBio Therapeutics (LOGC.O) skyrocketed on Monday after Britain’s AstraZeneca’s (AZN.L) said it would buy the U.S.-based gene therapy developer at a rare 660% premium for $68 million.
Source
Author: unknown